Mark Sheptoff Financial Planning, LLC Crispr Therapeutics Ag Transaction History
Mark Sheptoff Financial Planning, LLC
- $179 Million
- Q1 2024
A detailed history of Mark Sheptoff Financial Planning, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Mark Sheptoff Financial Planning, LLC holds 300 shares of CRSP stock, worth $16,203. This represents 0.01% of its overall portfolio holdings.
Number of Shares
300Holding current value
$16,203% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
549Shares Held
56.3MCall Options Held
2.91MPut Options Held
2.47M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.16MShares$441 Million3.97% of portfolio
-
Capital International Investors Los Angeles, CA7.84MShares$423 Million0.11% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.27MShares$177 Million0.16% of portfolio
-
Nikko Asset Management Americas, Inc.3.27MShares$177 Million2.23% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.7MShares$146 Million0.11% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.21B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....